Moderna reports positive – but still early – data from NIH Covid-19 vaccine trial
The company said eight participants dosed at 25 or 100 micrograms achieved concentrations of neutralizing antibodies against the SARS-CoV-2 virus at levels comparable to or exceeding those of Covid-19 patients who had recovered.